Zydus Nash
Prospective, Multi-Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium
Study phase: Other
Study phase (if other): 2b
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
Males and Females between 18 and 75 years of age
Primary disease category: Liver
Secondary disease categories: Liver
Sponsor: Zydus Therapeutics, Inc
Protocol number: Saro.20.002
Projected enrollment dates: October 2021 to October 2023
Official study title: Zydus Nash 2B